ArticleOral diseases2026
New Insights Into Diffuse Sclerosing Osteomyelitis: Is There a Role of ANA and Vitamin B6?
Article in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectDiffuse sclerosing osteomyelitis is a poorly understood chronic disease, which appears predominantly in the mandible. Female patients are more often affected than men. DSO is an ultra-rare disease and incidence is unknown; diagnosis can be very challenging; pathogenesis is poorly understood. SUBJECTS AND
methodsIn this prospective study, blood samples were collected from a total of 25 patients and analyzed to detect altered laboratory values to have insight into possible pathomechanism. Patients were divided into three groups: Group A: patients with DSO, Group B: patients with osteomyelitis and medication-related osteonecrosis, and Group C: healthy control group.
results44% of all patients in group A had elevated Vitamin B6 levels. Compared to groups B and C, these levels were statistically significantly higher (p = 0.011, p = 0.015). 23 patients had increased (92%) antinuclear-antibody-titer (ANA-Titer); in group B, 52% of all patients, and in the healthy control group, 44%.
conclusionsElevated ANA titers and elevated vitamin B6 levels provide a possible insight into the pathomechanisms of DSO. Therefore, in the search for the pathogenesis and etiology of DSO, autoimmune processes should also be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.